Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Effects of active psychosocial stimulation on social interactions of people with dementia living in a nursing home: a comparative study - ERRATUM.

Mabire JB, Gay MC, Vrignaud P, Garitte C, Jeon YH, Vernooij-Dassen M.

Int Psychogeriatr. 2018 Jun;30(6):923. doi: 10.1017/S1041610218001011. No abstract available.

PMID:
29970211
2.

Effects of active psychosocial stimulation on social interactions of people with dementia living in a nursing home: a comparative study.

Mabire JB, Gay MC, Vrignaud P, Garitte C, Jeon YH, Vernooij-Dassen M.

Int Psychogeriatr. 2018 Jun;30(6):921-922. doi: 10.1017/S1041610217002046. Epub 2017 Oct 2. Erratum in: Int Psychogeriatr. 2018 Jun;30(6):923.

PMID:
28965500
3.

Anxiety, emotional processing and depression in people with multiple sclerosis.

Gay MC, Bungener C, Thomas S, Vrignaud P, Thomas PW, Baker R, Montel S, Heinzlef O, Papeix C, Assouad R, Montreuil M.

BMC Neurol. 2017 Feb 23;17(1):43. doi: 10.1186/s12883-017-0803-8.

4.

A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model.

Saba C, Paoloni M, Mazcko C, Kisseberth W, Burton JH, Smith A, Wilson-Robles H, Allstadt S, Vail D, Henry C, Lana S, Ehrhart EJ, Charles B, Kent M, Lawrence J, Burgess K, Borgatti A, Suter S, Woods P, Gordon I, Vrignaud P, Khanna C, LeBlanc AK.

PLoS One. 2016 Feb 11;11(2):e0149194. doi: 10.1371/journal.pone.0149194. eCollection 2016.

5.

Social interactions between people with dementia: pilot evaluation of an observational instrument in a nursing home.

Mabire JB, Gay MC, Vrignaud P, Garitte C, Vernooij-Dassen M.

Int Psychogeriatr. 2016 Jun;28(6):1005-15. doi: 10.1017/S1041610215002483. Epub 2016 Jan 21.

PMID:
26790570
6.

Production of the Bengamide Class of Marine Natural Products in Myxobacteria: Biosynthesis and Structure-Activity Relationships.

Wenzel SC, Hoffmann H, Zhang J, Debussche L, Haag-Richter S, Kurz M, Nardi F, Lukat P, Kochems I, Tietgen H, Schummer D, Nicolas JP, Calvet L, Czepczor V, Vrignaud P, Mühlenweg A, Pelzer S, Müller R, Brönstrup M.

Angew Chem Int Ed Engl. 2015 Dec 14;54(51):15560-4. doi: 10.1002/anie.201508277. Epub 2015 Oct 30.

PMID:
26514647
7.

Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data.

Nunes M, Vrignaud P, Vacher S, Richon S, Lièvre A, Cacheux W, Weiswald LB, Massonnet G, Chateau-Joubert S, Nicolas A, Dib C, Zhang W, Watters J, Bergstrom D, Roman-Roman S, Bièche I, Dangles-Marie V.

Cancer Res. 2015 Apr 15;75(8):1560-6. doi: 10.1158/0008-5472.CAN-14-1590. Epub 2015 Feb 24.

8.

Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps.

Ilie M, Nunes M, Blot L, Hofman V, Long-Mira E, Butori C, Selva E, Merino-Trigo A, Vénissac N, Mouroux J, Vrignaud P, Hofman P.

Cancer Med. 2015 Feb;4(2):201-11. doi: 10.1002/cam4.357. Epub 2014 Dec 3.

9.

Mechanisms of resistance to cabazitaxel.

Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, Brassard D, Vrignaud P, Sikic BI.

Mol Cancer Ther. 2015 Jan;14(1):193-201. doi: 10.1158/1535-7163.MCT-14-0155. Epub 2014 Nov 21.

10.

Preclinical profile of cabazitaxel.

Vrignaud P, Semiond D, Benning V, Beys E, Bouchard H, Gupta S.

Drug Des Devel Ther. 2014 Oct 13;8:1851-67. doi: 10.2147/DDDT.S64940. eCollection 2014. Review.

11.

Efficacy of cabazitaxel in mouse models of pediatric brain tumors.

Girard E, Ditzler S, Lee D, Richards A, Yagle K, Park J, Eslamy H, Bobilev D, Vrignaud P, Olson J.

Neuro Oncol. 2015 Jan;17(1):107-15. doi: 10.1093/neuonc/nou163. Epub 2014 Aug 18.

12.

Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.

Sémiond D, Sidhu SS, Bissery MC, Vrignaud P.

Cancer Chemother Pharmacol. 2013 Sep;72(3):515-28. doi: 10.1007/s00280-013-2214-x. Epub 2013 Jul 3.

PMID:
23820961
13.

Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.

Vrignaud P, Sémiond D, Lejeune P, Bouchard H, Calvet L, Combeau C, Riou JF, Commerçon A, Lavelle F, Bissery MC.

Clin Cancer Res. 2013 Jun 1;19(11):2973-83. doi: 10.1158/1078-0432.CCR-12-3146. Epub 2013 Apr 15.

14.

Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.

Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, Job B, Dessen P, Bruno A, Pierré A, De Thé H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, Prévost G, Vrignaud P, Roman-Roman S, Duchamp O, Berthet C.

Clin Cancer Res. 2012 Oct 1;18(19):5314-28. doi: 10.1158/1078-0432.CCR-12-0372. Epub 2012 Jul 23.

15.

[Preclinical models in oncology].

Vrignaud P.

Bull Cancer. 2011 Nov;98(11):1355-61. doi: 10.1684/bdc.2011.1473. French.

16.

Generation of a conditionally transformed murine embryonic fibroblast cell line using doxycycline-dependent IGF-1R overexpression.

Graeser R, Vrignaud P, Esser N, Umber S, Zirrgiebel U, Chiron M, Schaechtele C, Kubbutat MH.

J Biomol Screen. 2012 Mar;17(3):339-49. doi: 10.1177/1087057111424310. Epub 2011 Oct 14.

PMID:
22002421
17.

Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma.

Geoerger B, Brasme JF, Daudigeos-Dubus E, Opolon P, Venot C, Debussche L, Vrignaud P, Vassal G.

Eur J Cancer. 2010 Dec;46(18):3251-62. doi: 10.1016/j.ejca.2010.06.005. Epub 2010 Jun 28.

PMID:
20591650
18.

Predictors of depression in multiple sclerosis patients.

Gay MC, Vrignaud P, Garitte C, Meunier C.

Acta Neurol Scand. 2010 Mar;121(3):161-70. doi: 10.1111/j.1600-0404.2009.01232.x. Epub 2010 Jan 12.

PMID:
20070277
19.

Principle of structural equation modeling for exploring functional interactivity within a putative network of interconnected brain areas.

de Marco G, Vrignaud P, Destrieux C, de Marco D, Testelin S, Devauchelle B, Berquin P.

Magn Reson Imaging. 2009 Jan;27(1):1-12. doi: 10.1016/j.mri.2008.05.003. Epub 2008 Jun 26. Review.

PMID:
18584986
20.

Differences in effective connectivity between dyslexic children and normal readers during a pseudoword reading task: an fMRI study.

Quaglino V, Bourdin B, Czternasty G, Vrignaud P, Fall S, Meyer ME, Berquin P, Devauchelle B, de Marco G.

Neurophysiol Clin. 2008 Apr;38(2):73-82. doi: 10.1016/j.neucli.2007.12.007. Epub 2008 Feb 4.

PMID:
18423328
21.

Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography.

Lavisse S, Lejeune P, Rouffiac V, Elie N, Bribes E, Demers B, Vrignaud P, Bissery MC, Brulé A, Koscielny S, Péronneau P, Lassau N.

Invest Radiol. 2008 Feb;43(2):100-11. doi: 10.1097/RLI.0b013e3181577cfc.

PMID:
18197062
22.

[Translational research and Cancer Plan].

Vassal G, Borella L, Pierre A, Pamphile R, Bourrie B, Meflah K, Amalric F, Pauporte I, Caillot JL, Formstecher P, Demers B, Dumontet C, Grégoire M, Lethiec F, Boue AM, Tonelli D, Pilsudski R, Van Hijfte L, Cailliot C, Vrignaud P, Merlin JL, Oudet P, Arnoux PY, Lassale C.

Bull Cancer. 2007 Dec;94(12):1107-11. French.

23.

Changes in effective connectivity during incidental and intentional perception of fearful faces.

de Marco G, de Bonis M, Vrignaud P, Henry-Feugeas MC, Peretti I.

Neuroimage. 2006 Apr 15;30(3):1030-7. Epub 2005 Nov 3.

PMID:
16271484
24.

[Rhythm of expression of BCL-2 protein of MA13/C mammaryadenocarcinoma bearing-mice].

Granda TG, Filipski E, Vrignaud P, Bissery MC, Lévi F.

Pathol Biol (Paris). 2003 Jun;51(4):220-1. French.

PMID:
12852995
25.

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma.

Granda TG, D'Attino RM, Filipski E, Vrignaud P, Garufi C, Terzoli E, Bissery MC, Lévi F.

Br J Cancer. 2002 Mar 18;86(6):999-1005.

26.

Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination.

Granda TG, Filipski E, D'Attino RM, Vrignaud P, Anjo A, Bissery MC, Lévi F.

Cancer Res. 2001 Mar 1;61(5):1996-2001.

27.

RPR 130401, a nonpeptidomimetic farnesyltransferase inhibitor with in vivo activity.

Vrignaud P, Bissery MC, Mailliet P, Lavelle F.

Ann N Y Acad Sci. 1999;886:249-51. No abstract available.

PMID:
10667231
28.

Docetaxel chronopharmacology in mice.

Tampellini M, Filipski E, Liu XH, Lemaigre G, Li XM, Vrignaud P, François E, Bissery MC, Lévi F.

Cancer Res. 1998 Sep 1;58(17):3896-904.

29.

Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice.

Bissery MC, Vrignaud P, Lavelle F, Chabot GG.

Ann N Y Acad Sci. 1996 Dec 13;803:173-80. Review. No abstract available.

PMID:
8993510
30.

Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.

Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud PY, Vrignaud P, Bissery MC, Veith JM, Pera P, Bernacki RJ.

J Med Chem. 1996 Sep 27;39(20):3889-96.

PMID:
8831755
31.

Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.

Bissery MC, Vrignaud P, Lavelle F, Chabot GG.

Anticancer Drugs. 1996 Jun;7(4):437-60.

PMID:
8826613
32.

Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.

Bissery MC, Vrignaud P, Lavelle F.

Semin Oncol. 1995 Dec;22(6 Suppl 13):3-16.

PMID:
8604451
33.

Synthesis and biological evaluation of amino-substituted benzo[f]pyrido[4,3-b] and pyrido[3,4-b]quinoxalines: a new class of antineoplastic agents.

Nguyen CH, Fan E, Riou JF, Bissery MC, Vrignaud P, Lavelle F, Bisagni E.

Anticancer Drug Des. 1995 Jun;10(4):277-97.

PMID:
7786395
34.

Preclinical evaluation of docetaxel (Taxotere).

Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, André S.

Semin Oncol. 1995 Apr;22(2 Suppl 4):3-16. Review.

PMID:
7740328
35.

Synthesis and structure-activity relationships of new antitumor taxoids. Effects of cyclohexyl substitution at the C-3' and/or C-2 of taxotere (docetaxel).

Ojima I, Duclos O, Zucco M, Bissery MC, Combeau C, Vrignaud P, Riou JF, Lavelle F.

J Med Chem. 1994 Aug 5;37(16):2602-8.

PMID:
7914541
36.

Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice.

Bissery MC, Nguyen CH, Bisagni E, Vrignaud P, Lavelle F.

Invest New Drugs. 1993 Nov;11(4):263-77.

PMID:
8157469
37.

Cellular pharmacology of 4'-iodo-4'-deoxydoxorubicin.

Schott B, Vrignaud P, Ries C, Robert J, Londos-Gagliardi D.

Br J Cancer. 1990 Apr;61(4):543-7.

38.

Assessment of the experimental model of transplanted C6 glioblastoma in Wistar rats.

San-Galli F, Vrignaud P, Robert J, Coindre JM, Cohadon F.

J Neurooncol. 1989 Sep;7(3):299-304.

PMID:
2795124
39.

Alteration of ganglioside composition and metabolism in doxorubicin-resistant rat tumoral cells.

Benchekroun MN, Vrignaud P, Montaudon D, Robert J.

Biochim Biophys Acta. 1988 Dec 16;963(3):553-7.

PMID:
3196750
40.

Free fatty acid uptake is increased in doxorubicin-resistant rat glioblastoma cells.

Vrignaud P, Robert J.

Biochim Biophys Acta. 1987 Aug 7;902(1):149-53.

PMID:
2886153
41.

Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver.

Ballet F, Vrignaud P, Robert J, Rey C, Poupon R.

Cancer Chemother Pharmacol. 1987;19(3):240-5.

PMID:
3581417
42.

Pharmacokinetics of doxorubicin in sarcoma patients.

Robert J, Bui NB, Vrignaud P.

Eur J Clin Pharmacol. 1987;31(6):695-9.

PMID:
3556376
43.

Fluorescence anisotropy of cell membranes of doxorubicin-sensitive and -resistant rodent tumoral cells.

Montaudon D, Vrignaud P, Londos-Gagliardi D, Robert J.

Cancer Res. 1986 Nov;46(11):5602-5.

44.

Fatty acid composition transport and metabolism in doxorubicin-sensitive and-resistant rat glioblastoma cells.

Vrignaud P, Montaudon D, Londos-Gagliardi D, Robert J.

Cancer Res. 1986 Jul;46(7):3258-61.

45.

Hepatic metabolism of doxorubicin in mice and rats.

Vrignaud P, Londos-Gagliardi D, Robert J.

Eur J Drug Metab Pharmacokinet. 1986 Apr-Jun;11(2):101-5.

PMID:
3770010
46.

Metabolism of doxorubicin and epirubicin in adult human hepatocytes in culture.

Ballet F, Robert J, Bouma ME, Vrignaud P, Infante R.

Pharmacol Res Commun. 1986 Apr;18(4):343-7.

PMID:
3461487
47.

Cellular pharmacology of doxorubicin in sensitive and resistant rat glioblastoma cells in culture.

Vrignaud P, Londos-Gagliardi D, Robert J.

Oncology. 1986;43(1):60-6.

PMID:
3941804
48.

Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients.

Vrignaud P, Eghbali H, Hoerni B, Iliadis A, Robert J.

Eur J Cancer Clin Oncol. 1985 Nov;21(11):1307-13.

PMID:
3865777
49.

Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.

Robert J, Vrignaud P, Nguyen-Ngoc T, Iliadis A, Mauriac L, Hurteloup P.

Cancer Treat Rep. 1985 Jun;69(6):633-40.

PMID:
3893693
50.

Tentative dose-monitoring of doxorubicin in lymphoma patients.

Robert J, Vrignaud P, Eghbali H, Nguyen-Ngoc T, Hoerni B.

Med Oncol Tumor Pharmacother. 1985;2(4):255-9.

PMID:
4087954

Supplemental Content

Loading ...
Support Center